Navigation Links
PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
Date:12/21/2011

BOSTON, Dec. 21, 2011 /PRNewswire/ -- To help emerging and mid-size biopharmaceutical companies address an increasingly challenging regulatory and commercial environment, PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it is introducing a series of executive briefings with clinical operations and outsourcing leaders worldwide.  During these forums, PAREXEL will discuss how a spectrum of proven operating practices and relationship models can significantly reduce timelines and costs and streamline protocols and programs.

Through these educational briefings, designed for emerging and mid-size biopharmaceutical companies, PAREXEL senior project leaders and teams will discuss customized solutions that can assist companies in achieving their short- and long-term development and commercialization milestones. The teams will address key issues that may impact critical areas for emerging and mid-sized biopharmaceutical companies, including:

  • Optimizing patient recruitment strategy
  • Meeting "first patient in" timelines
  • Accessing real-time data
  • Achieving database lock timelines
  • Accelerating the speed of site recruitment
  • Implementing risk management and contingency planning approaches
  • "Deep collaboration with emerging and mid-size biopharmaceutical companies has been part of our DNA for nearly 30 years. We are committed to continuing to work with these clients to help them navigate the next stages of their businesses in the 'niche-buster' era, and in a challenging regulatory and commercial environment," said Mark A. Goldberg, M.D., Chief Operating Officer, PAREXEL. "Through a flexible and innovative approach, we create solutions that are the 'right fit' for every client. We're looking forward to bringing th
    '/>"/>

    SOURCE PAREXEL International Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. PAREXEL Closes the Acquisition of ClinPhone
    2. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
    3. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
    4. PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
    5. PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference
    6. PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average
    7. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
    8. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
    9. PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
    10. PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress
    11. PAREXEL Expands Pioneering Asian Ethnobridging Expertise
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... September 02, 2014 Semiconductor industry leader ... Light-based Technologies (IYL 2015) visionary John Dudley were ... the international society for optics and photonics , last ... and Dudley along with other awards announced earlier this ... by James Harrington, during a gala banquet Wednesday evening ...
    (Date:9/2/2014)... detailed studies of what happens on the surface of ... other applications. A group of researchers from Lund University ... form across a large number of vertical nanowires, known ... of a cell and its surroundings takes place through ... that holds the cell together and that largely comprises ...
    (Date:9/2/2014)... 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") today ... for protecting personal data in Clinical Study Reports ... others. The document describes an approach to apply ... and other related clinical trial documents, and is ... of the TransCelerate CSR Redaction approach is to ...
    (Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014 ... announced that the U.S. Patent and Trademark Office (PTO) ... investigational medication being evaluated for weight loss. NB32 is ... bupropion SR. U.S. Patent No. 8,815,889 claims ... naltrexone and bupropion. The patent expires in 2024. If ...
    Breaking Biology Technology:Levinson, Dudley Win SPIE Directors’ and President’s Awards 2Levinson, Dudley Win SPIE Directors’ and President’s Awards 3Levinson, Dudley Win SPIE Directors’ and President’s Awards 4Nano-forests to reveal secrets of cells 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
    ... Lumiphore, Inc., a,biotechnology leader in the ... use in high-value applications, announced,that it has ... Inc.,Redwood City, California to apply Lumiphore products ... Under the agreement, Biophor Diagnostics holds the ...
    ... Inc. (OTC,Bulletin Board: NZYM) announced today the appointment ... on October 1, 2008. Since May,2008, Dr. Farkas ... over 13 years, experience with amino acid derivatives, ... and supply chain,management at Bachem Corporation, Novartis AG ...
    ... NxStage Medical,Inc. (Nasdaq: NXTM ), a leading manufacturer ... Chief Executive Officer,and Robert S. Brown, Chief Financial Officer, ... on October 6, 2008 at Le Parker,Meridien Hotel in ... Monday, October 6th at,2:30 p.m. ET. To listen to ...
    Cached Biology Technology:Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board 2Synthetech Announces New Director of Manufacturing 2NxStage Medical to Present at JMP Securities Healthcare Focus Conference 2
    (Date:9/2/2014)... truth; everyone has a tipping point. We all want to ... benefit is great enough. Now, scientists have confirmed the area ... , The result was published online this week in ... honest, even if lying is beneficial," said Lusha Zhu, the ... Virginia Tech Carilion Research Institute , where she works with ...
    (Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
    (Date:9/1/2014)... the U.S. diet showed some modest improvement in the ... in the consumption of unhealthy trans fats, but the ... and the poor. , , An unhealthy diet is ... Eating a healthy diet is an important part of ... trends in diet quality is important because it can ...
    Breaking Biology News(10 mins):Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Exceptionally well preserved insect fossils from the Rhône Valley 2Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
    ... its prestigious Clinical and Translational Science Award (CTSA) ... the amount of $29 million over the next ... wireless technology and bioinformatics toward individualizing medicine. ... Health and The Scripps Research Institute in partnership ...
    ... 22, 2013 More accurate and precise assessment of ... a particular gene that are present in a genome, ... cancer and other diseases including autoimmune disorders. However, ... labor intensive, or prohibitively costly, diminishing their effectiveness in ...
    ... New research shows that in sub-Saharan Africa the virus responsible ... distances and the African buffalo are important natural reservoirs for ... online open-access journal of the American Society for Microbiology, sheds ... 2 emerged in sub-Saharan Africa and identifies patterns of spread ...
    Cached Biology News:NIH awards Scripps Translational Science Institute $29 million grant 2NIH awards Scripps Translational Science Institute $29 million grant 3Bio-Rad's Droplet Digital PCR technology highlighted at ASHG Annual Meeting 2Foot and mouth disease in sub-Saharan Africa moves over short distances, wild buffalo are a problem 2
    Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
    p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
    Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
    ...
    Biology Products: